Kamura, Yuya
Sakamoto, Tatsuhiro
Yokoyama, Yasuhisa
Nishikii, Hidekazu
Sakata-Yanagimoto, Mamiko
Chiba, Shigeru
Obara, Naoshi http://orcid.org/0000-0001-6563-3093
Funding for this research was provided by:
Kyowa Hakko Kirin
Alexion Pharmaceuticals
Eisai
Otsuka Pharmaceutical
Bristol-Myers Squibb
Astellas Pharma
Ono Pharmaceutical
Sanofi Genzyme
Takeda Pharmaceutical Company
Chugai Pharmaceutical
Article History
Received: 15 March 2022
Revised: 6 May 2022
Accepted: 9 May 2022
First Online: 6 June 2022
Declarations
:
: YK, TS, YY, and HN, declare no conflicts of interest. NO received research funding from Kyowa Kirin, Alexion Pharma outside the submitted work. MS-Y received research funding from Eisai, Otsuka Pharmaceutical, and Bristol Myers Squibb outside the submitted work. SC received research funding from Astellas, Ono, Kyowa Kirin, Sanofi, Takeda, and Chugai, outside the submitted work.
Free to read: This content has been made available to all.